skip to main content


A Multicentre, 8-week, Single-arm, Open-label, Pragmatic Trial to Explore Acceptance and Performance of Using a Digital Medicine System with Healthcare Professionals and Adult Subjects with Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic.

What is involved? 

You will receive a new supply of your antipsychotic medication, which you will take for an 8 week period. These medication will have a sensor attached to them. You will also wear a patch on your stomach that the sensor will send a signal to once the medication has been ingested. The patch will then transmit this to the smartphone App.

If you join the study you will have up to 4 study visits: once or twice during the screening/baseline period and 2 times during the assessment period. At the end of your participation in the study, you will be contacted via telephone or you may be asked to come into the study site for a visit if the study doctor feels it is needed. The total study duration can be up to 10 weeks.

Twenty-four weeks before and after the screening/baseline visit, some of your healthcare information will be collected from your medical records to see how much you interact with your clinical team doctors.


To take part you must meet the following criteria:            

  • Aged 18 - 65 years of age

  • Have been diagnosed with Schizophrenia, Schizoaffective Disorder or First Episode Psychosis

  • Are currently taking oral (tablet) aripiprazole, olanzapine, quetiapine, or risperidone.

  • Possess a smartphone

  • Capacity to use the technology interface of the DigiMedS App on your smartphone


NOTE: You cannot take part if you are pregnant, vegetarian/vegan or do not meet the above criteria.

If you would like to take part or want more information please contact the study lead:

Study Contact: Marek Czeladzki


Tel: 02380 475943

Page Comments